One of the clinical trials with therapeutic agents targeting CSC in BC is the AVASTEM NCT01190345 trial, which evaluated the anticancer capacity of preoperative Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) receptor, along with conventional therapy in 75 participants with BC. Here, VEGFA is linked to breast cancer.